PharmaTelevision - AM-Pharma: Developing innovative alternatives to antibiotics

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AM-Pharma: Developing innovative alternatives to antibiotics

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, Fintan Walton speaks with Bart Wuurman, CEO of AM-Pharma, a biopharmaceutical company, based in the Netherlands, that is focused on the development and commercialisation of innovative therapeutics that treat inflammatory diseases and infectious diseases. The company is conducting Phase II clinical trials for two products; Alkaline Phosphatase for acute renal failure and ulcerative colitis; and Selective Immune Response Amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. With AM-Pharma having completed Series B funding and about to begin Series C, Dr. Wuurman is investigating a range of funding possibilities including partnerships with top-tier development companies, licensing deals, and even a potential IPO offering.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins of AM-Pharma and types of products.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here live in Madrid. On this show I have Bart Wuurman, who is the CEO of AM-Pharma based in Utrecht in the Netherlands, welcome to the show.

Bart Wuurman:

Thank you very much Fintan for the invite.

Fintan Walton:

AM-Pharma is a product of two companies, own products have been brought together into AM-Pharma you are a very focused company on replacement therapy effectively, could you tell us a little bit about both the origins of AM-Pharma and the types of products it's pursuing?

Bart Wuurman:

Yeah, well we have two products one product comes from the University of Groningen originally and the other one from the University of Leiden and they're brought together because they have one unique feature that is they have in common is that they are both indigenous molecules that are slightly modified and they both use physiological processes to fight disease and which gives an interesting concept because their novel motive actions but because it uses physiological processes and then indigenous molecules and therefore safe, we medicate quite a lot of the risks that are associated with this novel concept.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Bart Wuurman

Chief Executive Officer

Dr Bart Wuurman is Chief Executive Office of AM-Pharma and has 18 years of International Pharma and Biotechnology Industry experience. After graduating in Pharmaceutical Sciences in the Netherlands in 1987, he has worked in marketing and business development positions for Organon, Medeva and Antisoma. He has been instrumental to a number of strategically important licensing deals, the last of which was the AntisomaRoche Oncology Alliance, worth $500 million, signed in November 2002. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, UK, where he was responsible for the successful restructuring and refinancing of the company.

AM-Pharma

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. Their products are based on endogenous proteins and (protein derived) peptides, optimized to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms: Enhancing Toll-Like-Receptor mediated activation of innate immune cells Dephosphorylation of extracellular substrates to influence disease processes So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline-Phosphatase and hLF1-11, up to the point of initial proof of clinical efficacy and safety.